All News

I was diagnosed with a rare cancer in 2007, and it shaped who I am today.

Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until PSA recurrence and failure.

A first patient received samuraciclib plus Orserdu in a phase 2 trial, a treatment combination for some patients with HR-positive, HER2-negative metastatic breast cancer.

One expert explained how care team aspects such as open dialogue, support and validation can help to inform patients with MPN about psychosocial needs that tend to be unmet.

Sometimes, it is better to keep things to yourself when it comes to cancer.

The Food and Drug Administration approved Keytruda plus chemotherapy for patients with locally advanced unresectable or metastatic biliary tract cancer.

After experiencing a relapse of acute myeloid leukemia, I thought about giving up, but then remembered my guiding principles.

The FDA will review SLS009 for the treatment of peripheral T-cell lymphoma, a rare and aggressive type of blood cancer.

In honor of Liver Cancer Awareness Month, CURE® highlighted some of the most impactful liver cancer developments from 2023.

I found comfort and peace on social media from different cancer communities.

Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free survival.

Autoimmune diseases in patients with CLL are separate from CLL, which calls for different treatments.

A phase 2 study evaluated meaningful activity from lifileucel for patients with advanced mucosal melanoma who experienced disease progression on immune checkpoint inhibitors.

Patients with metastatic or recurrent head and neck squamous cell carcinoma had durable antitumor activity, according to findings from a phase 2 trial.

Sexual activity and vaginal dilation could make follow-up examinations more “tolerable” and “pain free” for survivors of cervical cancer after radiotherapy.

Who knew how impactful socks could be!

Prostatic urethra length may help predict which patients with prostate cancer are more likely to experience chronic urinary side effects after radiation treatment, according to a recent study.

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

The Food and Drug Administration approved Loqtorzi with and without chemotherapy for certain patients with nasopharyngeal carcinoma.

Amanda Smith, a registered nurse with Huntsman Cancer Institute, explained the impact early satiety can have on patients with MPNs and why communication with their care team is important.

Jemperli plus chemotherapy demonstrated improvement in overall survival compared with Keytruda and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.

A recent phase 2 study showed promising survival improvements with neoadjuvant Libtayo in patients with cutaneous squamous cell carcinoma after a year and a half follow up.

Keytruda plus the combination of Herceptin and chemotherapy led to an improvement in progression-free survival versus placebo plus Herceptin and chemotherapy in the first-line treatment of some patients with metastatic HER2-positive gastric or gastroesophageal junction cancer.

According to the Food and Drug Administration, the shortage of Novartis’ prostate cancer treatment Pluvicto, which began in March, has been resolved, with the manufacturer expecting a continued expansion of supply.

The Food and Drug Administration accepted an Investigational New Drug application for MB-109, a novel agent that combines two mechanisms to treat recurrent glioblastoma and high-grade astrocytroma.

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.

It’s key for patients with MPN-related fatigue to communicate changes they feel, especially as they “know their bodies very well,” a nurse told CURE®.